Seroatlas · Human Serome Atlas

METTL2A

tRNA N(3)-cytidine methyltransferase METTL2A

Also known as: FLJ12760, MET2A_HUMAN, METTL2

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q96IZ6
Gene: METTL2A
Ensembl: ENSG00000087995
Chromosome: 17
Canonical length: 378 aa
Protein class: Plasma proteins, Predicted intracellular proteins

OverviewNCBI Gene

Enables tRNA (cytidine-3-)-methyltransferase activity. Involved in tRNA methylation. Located in cytoplasm. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

378 residues, UniProt reviewed canonical sequence.

>Q96IZ6|METTL2A
     1  MAGSYPEGAP AVLADKRQQF GSRFLRDPAR VFHHNAWDNV EWSEEQAAAA ERKVQENSIQ
    61  RVCQEKQVDY EINAHKYWND FYKIHENGFF KDRHWLFTEF PELAPSQNQN HLKDWFLENK
   121  SEVPECRNNE DGPGLIMEEQ HKCSSKSLEH KTQTLPVEEN VTQKISDLEI CADEFPGSSA
   181  TYRILEVGCG VGNTVFPILQ TNNDPGLFVY CCDFSSTAIE LVQTNSEYDP SRCFAFVHDL
   241  CDEEKSYPVP KGSLDIIILI FVLSAIVPDK MQKAINRLSR LLKPGGMMLL RDYGRYDMAQ
   301  LRFKKGQCLS GNFYVRGDGT RVYFFTQEEL DTLFTTAGLE KVQNLVDRRL QVNRGKQLTM
   361  YRVWIQCKYC KPLLSSTS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against METTL2A can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.34
Highest tissue expression: 5.9 nTPM

Expression across tissuesHPA

Tissue

skeletal muscle: 5.9 nTPM
cerebral cortex: 3.7 nTPM
skin: 3.6 nTPM
amygdala: 2.9 nTPM
thyroid gland: 2.9 nTPM
basal ganglia: 2.8 nTPM

Single-cell type

erythrocyte progenitors: 45 nCPM
megakaryocytes: 43 nCPM
cytotrophoblasts: 32 nCPM
esophageal basal cells: 32 nCPM
alveolar cells type 1: 32 nCPM
late primary spermatocytes: 31 nCPM

Immune cell

NK-cell: 2.4 nTPM
neutrophil: 2.2 nTPM
gdT-cell: 1.9 nTPM
naive B-cell: 1.8 nTPM
naive CD8 T-cell: 1.8 nTPM
basophil: 1.7 nTPM

Brain region

cerebellum: 8.9 nTPM
hypothalamus: 8.5 nTPM
choroid plexus: 8.4 nTPM
white matter: 8.4 nTPM
cerebral cortex: 8.2 nTPM
thalamus: 8.2 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.35
gnomAD pLI: 0
gnomAD missense Z: 0.07
DepMap mean gene effect: -0.14
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 9% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

tRNA (cytidine-3-)-methyltransferase activity

Cellular components

cytoplasm

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of METTL2A in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

DALRD3

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads METTL2A as an antibody target. Whether an autoantibody or antibody against METTL2A could matter depends on whether native METTL2A is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

METTL2A is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label METTL2A as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...